These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1379 related articles for article (PubMed ID: 8601728)

  • 1. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes.
    Ohta Y; Kijima H; Kashani-Sabet M; Scanlon KJ
    J Invest Dermatol; 1996 Feb; 106(2):275-80. PubMed ID: 8601728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.
    Ohta Y; Kijima H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Nucleic Acids Res; 1996 Mar; 24(5):938-42. PubMed ID: 8600463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.
    Koizumi M; Kamiya H; Ohtsuka E
    Gene; 1992 Aug; 117(2):179-84. PubMed ID: 1639266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.
    Chang MY; Won SJ; Liu HS
    J Cancer Res Clin Oncol; 1997; 123(2):91-9. PubMed ID: 9030247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ras oncogene activation does not induce sensitivity to natural killer cell-mediated lysis in human melanoma.
    van Elsas A; van Deursen E; Wielders R; van den Berg-Bakker CA; Schrier PI
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):117S-121S. PubMed ID: 7963672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene.
    Castelli C; Sensi M; Lupetti R; Mortarini R; Panceri P; Anichini A; Parmiani G
    Cancer Res; 1994 Sep; 54(17):4785-90. PubMed ID: 8062279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
    Husain Z; FitzGerald GB; Wick MM
    J Invest Dermatol; 1990 Nov; 95(5):571-5. PubMed ID: 2121834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H-ras ribozyme-mediated alteration of the human melanoma phenotype.
    Ohta Y; Tone T; Shitara T; Funato T; Jiao L; Kashfian BI; Yoshida E; Horng M; Tsai P; Lauterbach K
    Ann N Y Acad Sci; 1994 May; 716():242-53; discussion 253-6. PubMed ID: 8024198
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
    Eastham JA; Ahlering TE
    J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture.
    Giannini CD; Roth WK; Piiper A; Zeuzem S
    Nucleic Acids Res; 1999 Jul; 27(13):2737-44. PubMed ID: 10373591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncorrelative c-myc and ras oncogene expression in squamous cell carcinoma cells with tumorigenic potential.
    Shuler C; Kurian P; French BT; Noyes I; Sital N; Hollering J; Trewyn RW; Schuller D; Milo GE
    Teratog Carcinog Mutagen; 1990; 10(1):53-65. PubMed ID: 1693449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
    Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
    Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
    Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
    Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.